Sign in to view content

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

Vrinda S. Hershberger, MD, PhD

Video
Published 2021

Related

Treatment course and outcomes of neovascular age-related macular degeneration in patients receiving intraocular pressure-lowering drops
Bobeck S Modjtahedi, MD
On Demand Cases, Courses, and Papers
2019
Higher-Order OCT Analysis From the HAWK Study: Longitudinal Dynamics in Fluid Burden, Outer Retinal Integrity, and Subretinal Hyperreflective Material
Justis P. Ehlers, MD, FASRS
On Demand Cases, Courses, and Papers
2021
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2021

Category: AMD-Neovascular

See more